Core Insights - The emergence of AI technology is expected to significantly enhance the efficiency of drug development in the biopharmaceutical industry, potentially leading to a transformative impact on investment returns in the sector [1][3][4] Industry Overview - The global AI-enabled drug development market has grown from $5.37 billion in 2019 to $11.9 billion in 2023, with a compound annual growth rate (CAGR) of 22%. It is projected to reach $74.6 billion by 2032, with a CAGR of 22.6% [4] - AI is increasingly integrated into the entire drug development process, from target discovery to clinical trial design and even production and sales [3][4] Company Insights - Insilico Medicine is a leading company in the AI drug development field, focusing on validating the commercial viability of AI in drug discovery. It has made significant progress in clinical trials compared to its peers in the AI+Biotech sector [1][4] - The company has developed an integrated AI drug discovery platform, Pharma.AI, which covers the entire drug development process and has produced 27 preclinical candidate compounds and 13 drug pipelines that have received clinical trial approval [7] - Insilico Medicine's typical pipeline products can advance from discovery to preclinical stages in 12-18 months, compared to the traditional 3-6 years, showcasing a clear efficiency advantage [7] Challenges and Future Directions - Despite advancements, no drug designed by AI has yet been approved for commercialization, which remains a significant challenge for the AI drug development industry [8] - Insilico Medicine is actively working to accelerate drug development processes and is exploring collaborations to expedite the approval of its drug candidates [8] - The competition among AI drug companies is expected to shift from algorithm superiority to data resource advantages, emphasizing the need for extensive data accumulation for model training [10][11] Data Utilization - Data is crucial for AI technology, and the ability to leverage real-world medical data from hospitals is seen as highly valuable for both traditional and AI drug companies [11] - There are regulatory challenges in accessing and utilizing medical data in China, which limits its commercial potential [12] - Suggestions have been made to separate data ownership and usage rights to facilitate the flow of medical data for pharmaceutical use, drawing on examples from the U.S. [12]

Core Insights - Insilico Medicine, a clinical-stage biopharmaceutical company driven by generative artificial intelligence, has announced a strategic drug development collaboration with Qilu Pharmaceutical Group and its subsidiary, Shanghai Qilu Pharmaceutical Research Center [1] - The partnership will leverage Insilico's proprietary Pharma.AI platform to develop small molecule inhibitors targeting specific pathways, focusing on the management of cardiovascular and metabolic diseases [1] - The total contract value exceeds HKD 931 million, which includes milestone payments for development and sales, as well as a share of future net sales [1] Company Summary - Insilico Medicine specializes in AI-driven drug discovery and development, particularly in the field of small molecule drugs for metabolic diseases [1] - Qilu Pharmaceutical Group will handle the subsequent development and commercialization of the drugs developed through this collaboration [1] Financial Summary - The collaboration agreement is valued at over HKD 931 million, indicating significant financial commitment and potential for revenue generation through milestone payments and sales sharing [1]

Group 1 - Wangshan Wangshui-B (02630) surged over 14%, reaching a new high, following the announcement of significant antiviral research against Nipah virus by a team including researchers from the Wuhan Institute of Virology and Shanghai Institute of Materia Medica [1] - Zhaoyi Innovation (03986) increased by over 5.6%, with a forecasted revenue of approximately 9.2 billion yuan for 2025, representing a year-on-year growth of about 25%, and a projected net profit of around 1.61 billion yuan, up 46% [1] - Youran Dairy (09858) rose over 4% after completing a placement of 299.25 million shares at a price of 3.92 HKD per share [1] Group 2 - Yijun Group Holdings (02442) experienced a decline of over 39%, despite a previous surge of 4.4 times since its relisting on December 3, 2022 [2] - Alibaba-W (09988) saw a rise of 1.82% after the launch of its Qwen3-Max-Thinking model, which has over 1 trillion parameters and 36 trillion tokens of pre-training data [2][3] - Junda Co., Ltd. (02865) fell nearly 11%, with a drop of over 30% from its recent peak, following an announcement of a strategic investment in Shanghai Xingyi Xinneng Technology Co., Ltd. [2] Group 3 - WanGuo Data-SW (09698) increased by over 6%, also in response to the launch of Alibaba's Qwen3-Max-Thinking model [3] - MicroPort Scientific Corporation-B (02160) dropped 11% after announcing a proposed share consolidation [3] - Valiant Pharmaceuticals-B (09887) rose nearly 4% after receiving orphan drug designation from the European Commission for its core product [4] Group 4 - AI application software stocks in the US saw significant gains, with Cloudflare (NET.US) up 9.17% and Zoom Communications (ZM.US) up 11.28% [5] - Apple (AAPL.US) rose 2.97% ahead of its Q1 2026 earnings report, with expected revenue growth of 11.3% year-on-year to 138.42 billion USD [5] - Intel (INTC.US) continued its decline, falling 5.72% after a previous drop, with revenue expectations for Q1 2026 significantly below market forecasts [5] Group 5 - Kingsoft Cloud (KC.US) increased by 8.1% following a strategic upgrade of its AI training and deployment platform [6] - Precious metals stocks saw pre-market gains, with First Majestic Silver (AG.US) up 1.1% as gold prices reached historical highs [6]

消息面上，1月27日，英矽智能发布公告，英矽智能已与齐鲁制药集团及其附属公司上海齐鲁制药研究 中心，达成药物研发战略合作并签署相关协议。透过该合作，双方将依托英矽智能自有Pharma.AI解决 方案，针对特定靶点开展小分子抑制剂合作开发，关注心血管与代谢类疾病领域管理。 智通财经APP获悉，英矽智能(03696)涨近5%，截至发稿，涨4.5%，报59.2港元，成交额3446.85万港 元。 根据该协议的条款，英矽智能将利用自主搭建的Pharma.AI平台，关注用于代谢疾病领域的新颖小分子 药物设计与优化，齐鲁制药将负责后续开发与商业化工作。该协议总额超9.31亿港元，包含开发和销售 里程碑付款，以及单位数的后续净销售额分成。 ...

每经AI快讯，1月27日，英矽智能在港交所公告，公司已与齐鲁制药集团及其附属公司上海齐鲁制药研 究中心，达成药物研发战略合作并签署相关协议。透过该合作，双方将依托英矽智能自有Pharma.AI解 决方案，针对特定靶点开展小分子抑制剂合作开发，关注心血管与代谢类疾病领域管理。该协议总额超 过9.31亿港元，包含开发和销售里程碑付款，以及单位数的后续净销售额分成。 ...

Core Viewpoint - The collaboration between Insilico Medicine (03696) and Qilu Pharmaceutical Group aims to accelerate the development of innovative therapies for cardiovascular and metabolic diseases, with a total agreement value exceeding HKD 931 million [1] Group 1: Collaboration Details - Insilico Medicine has signed a strategic drug development cooperation agreement with Qilu Pharmaceutical and its subsidiary Shanghai Qilu Pharmaceutical Research Center [1] - The partnership will leverage Insilico's proprietary Pharma.AI solution to develop small molecule inhibitors targeting specific pathways in the management of cardiovascular and metabolic diseases [1] Group 2: Financial Aspects - The agreement includes milestone payments for development and sales, as well as a share of subsequent net sales based on unit numbers [1] - The total value of the agreement is over HKD 931 million, indicating significant financial commitment from both parties [1]

Core Viewpoint - The collaboration between 英矽智能 (InSilico Medicine) and 齐鲁制药集团 (Qilu Pharmaceutical Group) focuses on drug development in the cardiovascular and metabolic disease management sectors, leveraging InSilico's Pharma.AI platform for small molecule inhibitor development [1] Group 1: Collaboration Details - 英矽智能 has signed a strategic cooperation agreement with 齐鲁制药集团 and its subsidiary 上海齐鲁制药研究中心 (Shanghai Qilu Pharmaceutical Research Center) [1] - The partnership will utilize InSilico's proprietary Pharma.AI solutions to develop small molecule inhibitors targeting specific disease pathways [1] Group 2: Financial Aspects - The total value of the agreement exceeds 931 million HKD, which includes milestone payments for development and sales, as well as a share of subsequent net sales [1]

Core Viewpoint - The collaboration between Insilico Medicine and Qilu Pharmaceutical Group focuses on drug development in the cardiovascular and metabolic disease sectors, leveraging Insilico's Pharma.AI platform for small molecule inhibitor development [1] Group 1: Partnership Details - Insilico Medicine has signed a strategic cooperation agreement with Qilu Pharmaceutical Group and its subsidiary, Shanghai Qilu Pharmaceutical Research Center [1] - The agreement involves the development of novel small molecule drugs targeting metabolic diseases, with Insilico utilizing its Pharma.AI platform [1] Group 2: Financial Aspects - The total value of the agreement exceeds HKD 931 million, which includes milestone payments for development and sales, as well as a share of subsequent net sales [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 英矽智能 （於開曼群島註冊成立的有限公司） （股份代號：3696) 自願公告 英矽智能與齊魯製藥達成超過9.31億港元的藥物研發合作 加速心血管與代謝類疾病創新療法開發 本公告由英矽智能（「本公司」，連同其附屬公司統稱「本集團」）自願作出，以告知 本公司股東及潛在投資者有關本集團的最新業務更新。 本公司董事會（「董事會」）欣然宣佈，英矽智能已與齊魯製藥集團及其附屬公司上 海齊魯製藥研究中心（「齊魯製藥」），達成藥物研發戰略合作（「該合作」）並簽署相 關協議（「該協議」）。 透過該合作，雙方將依託英矽智能自有Pharma.AI解決方案，針對特定靶點開展小 分子抑制劑合作開發，關注心血管與代謝類疾病領域管理。 根據該協議的條款，英矽智能將利用自主搭建的Pharma.AI平台，關注用於代謝疾 病領域的新穎小分子藥物設計與優化，齊魯製藥將負責後續開發與商業化工作。 該協議總額超9.31億港元，包含開發和銷售里程碑 ...

Group 1 - Sanhua Intelligent Control (02050) saw a decline of over 3.4% after announcing a share reduction plan involving the actual controller and several directors, with a total of up to approximately 10.2 million A-shares to be sold between February 24, 2026, and May 23, 2026 [1] - Tuo Yun Biotechnology (01332) experienced a significant drop of over 60%, nearly erasing gains since October 2022, following stock movements involving major shareholders [1] - Zhongwei New Materials (02579) increased by over 5% as the company announced securing 5-6 billion wet tons of nickel ore resources and establishing four nickel raw material industrial bases in Indonesia [1] Group 2 - InnoCare Pharma (03696) rose over 6%, reaching a new high of 62.9 HKD, after receiving FDA approval for its oral NLRP3 inhibitor ISM8969 for Parkinson's disease treatment [2] - Solar stocks surged, with Kaisa New Energy (01108) up 17.85% and other companies like Fuyao Glass (06865) and Xinyi Solar (00968) also showing significant gains, driven by a report indicating a new phase in commercial space deployment [2] - Jiangnan Buyi (03306) fell nearly 7% after announcing a placement of 14.535 million shares at a discount to the market price [2] Group 3 - Lithium stocks rose, with Ganfeng Lithium (01772) up 5.22% and Tianqi Lithium (09696) up 2.88%, following a report of a significant increase in lithium carbonate contract prices [3] - Rongchang Bio (09995) increased nearly 2% after UBS expressed a positive outlook on its collaboration with AbbVie, which includes substantial milestone payments [4] - DCH Holdings (00179) fell nearly 7% as it reported a slight decline in revenue for the nine months ending December 31, 2025 [4] Group 4 - Gold stocks rebounded, with Chifeng Jilong Gold Mining (06693) up 6.99% and others also showing gains, as spot gold prices reached a new high of over $4,960 per ounce [4] - Bitgo Holdings (BTGO.US) debuted on the US stock market, rising 2.72% as a leading cryptocurrency custody provider [5] - Rare earth stocks surged, with USA Rare Earth (USAR.US) up 17.49% after announcing partnerships to advance its Round Top project [5] Group 5 - The Nasdaq Golden Dragon China Index opened up 1.6%, with major Chinese stocks like Li Auto (LI.US) and Alibaba (BABA.US) showing gains, supported by comments from the People's Bank of China regarding potential monetary easing [6] - Abbott (ABT.US) fell 10.04% after reporting lower-than-expected sales for Q4 2025, despite a year-over-year increase in adjusted EPS [7] - Alibaba (BABA.US) rose 5.05% as it plans to list its semiconductor division, benefiting from investor interest in competing with Nvidia [7]